We are live on ! Find out more
MYGN icon

Myriad Genetics

186 hedge funds and large institutions have $2B invested in Myriad Genetics in 2024 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 72 increasing their positions, 63 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,852% more call options, than puts

Call options by funds: $6.32M | Put options by funds: $324K

15% more capital invested

Capital invested by funds: $1.74B → $2B (+$264M)

14% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 63

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

4% less funds holding

Funds holding: 194186 (-8)

5.97% less ownership

Funds ownership: 110.38%104.41% (-6%)

28% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 29

Holders
186
Holders Change
-8
Holders Change %
-4.12%
% of All Funds
2.68%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
21
Increased
72
Reduced
63
Closed
29
Calls
$6.32M
Puts
$324K
Net Calls
+$6M
Net Calls Change
+$4.27M

MYGN Hedge Fund Activity: Q1 2024 in Review

186 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2024, worth a combined $2B — up 15% from $1.74B a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of MYGN and 21 opened new positions — a net loss of 8 holders — while 63 trimmed existing stakes and 72 added.

The largest buyer was Wellington Management Group, adding an estimated $18.1M. The largest seller was D.E. Shaw & Co, cutting an estimated $11.5M.

  • 186 institutional investors held Myriad Genetics (MYGN) as of Q1 2024, down from 194 in Q4 2023.
  • Funds reported $2B of Myriad Genetics stock for Q1 2024, up 15% quarter-over-quarter.
  • 21 funds opened new Myriad Genetics positions in Q1 2024 and 29 closed out, a net change of -8 holders.
  • The largest Myriad Genetics buyer in Q1 2024 was Wellington Management Group, an estimated $18.1M added.
  • The largest Myriad Genetics seller in Q1 2024 was D.E. Shaw & Co, an estimated $11.5M sold.

Based on aggregated 13F filings for Q1 2024.